FIELD: medicine, pharmacy.
SUBSTANCE: invention proposes a pharmaceutical composition possessing the fibrinolytic effect and comprising as an active substance a modified activator of plasminogen of urokinase type mAPUT22, mannitol and sodium chloride taken in the following ratio of components, wt.-%: mAPUT22, 2.8-4.2; mannitol, 31.1-38.8, and sodium chloride, up to 100. This pharmaceutical composition can be used in neurosurgery in treatment of intracranial hematomas arising in hemorrhagic insults. The composition possesses high specific fibrinolytic activity and doesn't cause dangerous adverse effects in removing intracranial hematomas.
EFFECT: valuable medicinal properties of pharmaceutical composition.
2 cl, 8 tbl, 6 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING INTRACEREBRAL BLEEDING CASES | 2005 |
|
RU2314838C2 |
| METHOD FOR MINIMALLY INVASIVE REMOVAL OF INTRACRANIAL NON-TRAUMATIC HEMATOMAS | 2021 |
|
RU2819167C2 |
| METHOD OF TREATING INTRACEREBRAL HEMORRHAGE OF BRAIN | 2012 |
|
RU2494684C1 |
| PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC AND FIBRINOLYTIC EFFECT | 2002 |
|
RU2216348C1 |
| METHOD FOR TREATMENT OF ISCHEMIC STROKE | 2018 |
|
RU2670203C1 |
| METHOD OF TREATING ACUTE THROMBOSIS OF RETINA VEINS | 2010 |
|
RU2416402C1 |
| METHOD OF DIAGNOSING CHANGES IN PERIFOCAL REGION DURING SMALL SUPRATENTORIAL INTRACEREBRAL BLEEDING | 2008 |
|
RU2363380C1 |
| TWO-COMPONENT PHARMACEUTICAL COMPOSITION HAVING FIBRINOLYTIC EFFECT | 2020 |
|
RU2765043C1 |
| METHOD FOR REMOVING INTRACEREBRAL HEMATOMAS OF NONTRAUMATIC ORIGIN | 2002 |
|
RU2230497C2 |
| METHOD FOR TREATING HEMORRHAGES INTO INTERNAL MEDIA AND MEMBRANES OF AN EYE ACCOMPANIED WITH BLOOD PLATELETS HYPERAGGREGATION | 1998 |
|
RU2161020C2 |
